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RESEARCH ARTICLE
Risk Factors for the Development of Critical Illness Polyneuropathy and 
Myopathy in a Pediatric Intensive Care Unit
Abstract
Objective
Critical illness polyneuropathy and myopathy (CIPNM) is a major complication 
of severe critical illness. Previous studies have suggested that many risk factors 
such as sepsis, multiorgan failure, and neuromuscular blocking agents play a 
role in CIPNM pathogenesis. The aim of this study was to evaluate possible risk 
factors in the development of CIPNM in a pediatric intensive care unit (PICU).
Materials & Methods
In this observational study, we recruited 57 patients admitted in the PICU of the 
Tabriz Pediatric Hospital. CIPNM was diagnosed in 13 (22.8%) patients on the 
basis of the clinical and electrodiagnostic findings. Different variables such as 
age, sex, the pediatric risk of mortality (PRISM) score, duration of mechanical 
ventilation and PICU stay, accompanying pathologic conditions, medications, 
and in-hospital outcome were compared between the CIPNM and non-CIPNM 
groups.
Results
Compared to the non-CIPNM patients, the CIPNM patients showed significantly 
more frequent sepsis (6.8% vs. 38.5%, odds ratio [OR] = 8.5, 95% confidence 
interval [CI] = 1.7–43.1) and multiorgan dysfunction (43.2% vs. 76.9%, OR = 
4.4, 95% CI = 1.1–18.2). Midazolam was administered more frequently in the 
non-CIPNM group than in the CIPNM group (88.6% vs. 53.8%, OR = 0.2, 95% 
CI = 0.0–0.6). There was no significant difference between the 2 groups with 
respect to parameters such as age, sex, PRISM score, duration of mechanical 
ventilation and PICU stay, other accompanying pathologic conditions, and 
other medications. The mortality rate was 4.5% in the non-CIPNM group and 
15.4% in the CIPNM group. 
In the multivariable analysis, sepsis and midazolam administration were the 
only significant contributors to the development of CIPNM.
Conclusion
Sepsis is an independent risk factor for the development of CIPNM. However, 
midazolam administration seems to be an independent protective factor against 
CIPNM.
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Introduction
Neuromuscular weakness delays recovery from critical illness. The 2 types of 
acquired neuromuscular complications are critical illness myopathy and critical 
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from the study: patients with Guillain–Barre syndrome, 
acute and chronic spinal lesions, hypophosphatemia, 
and myasthenia gravis; patients who developed central 
nervous system disorders and complications during 
their hospitalization; and patients with confirmed 
neuromuscular diseases that cause weakness and 
paralysis. 
The patients admitted to the PICU underwent neurologic 
examinations twice a week. The examinations included 
evaluation of motor disorders, decrease in muscle mass, 
loss of sensation, and the status of the tendon reflexes. 
Patients receiving muscle relaxants and neuromuscular 
blocking agents were examined 3 days after the cessation 
of administration of these agents. On the basis of the 
findings of the clinical and neurologic examinations, 
electromyography (EMG) and the nerve conduction 
velocity (NCV) test were performed in patients who 
were receiving muscle relaxants, had weakness and/
or peripheral paralysis, had prolonged weakness and 
paralysis, and had difficulty in weaning from the 
ventilator or increase in PCO2 levels after remission 
of the primary disease. On the basis of the results of 
the above-mentioned examinations, the patients were 
categorized into 2 groups: the CIPNM group (if their 
peripheral weakness was confirmed) and the non-
CIPNM group. 
The CIPNM patients were followed up after 6 weeks by 
using neurologic and electrophysiologic analyses. 
The time of administration and the dose of medications 
such as midazolam, pancuronium, steroid, and 
aminoglycoside were recorded. The levels of creatinine 
phosphokinase and liver enzymes and the sedimentation 
rate were examined every 2 weeks. The urine myoglobin 
level was also measured in this group to check for 
myopathy. 
Muscle biopsies were performed in patients with 
probable ICU neuromuscular syndrome who were 
doubted neuromuscular system disorders without known 
neuromuscular disease. The presence of sepsis and 
multiorgan dysfunction in the patients was evaluated and 
recorded by the professors of the PICU ward by using 
the required diagnostic criteria. 
This study was approved by the Ethics Committee of the 
Tabriz Medical Science University. Written consent was 
obtained from the parents, and the patients’ information 
illness polyneuropathy. However, these 2 terms have 
some overlaps and instead of that critical illness 
polyneuropathy and myopathy (CIPNM) is preferred 
that is a sequela of diffused peripheral neuropathy 
(1,2). Bolton et al. first described that in 1984 in an 
adult intensive care unit (ICU) (2). CIPNM has been 
rarely diagnosed in children, and it is unclear whether 
the symptoms of CIPNM observed in children differ 
from those observed in adults (1). CIPNM is mostly 
asymptomatic, but sometimes it can be symptomatic. 
About 70% of the patients show electrophysiologic 
changes associated with axonal polyneuropathy, and 
30% of the patients show clinical signs such as flaccid 
tetraparesis or paraparesis and difficulties in weaning 
from mechanical ventilation (3,4,5). Two important 
causes of CIPNM are thought to be sepsis and multiorgan 
failure (1,2). CIPNM mostly develops in patients who 
have been ventilator-dependent for at least a week (6). 
Zifko et al. observed that 70% of the patients with sepsis 
showed critical illness polyneuropathy (7). Eriksson 
reported that CIPNM was associated with multiorgan 
failure caused by sepsis or trauma (8). However, there 
is an important association between CIPNM and 
atrophy caused by immobility, acute polyneuropathy, 
and steroid-induced myopathy. Multiorgan dysfunction, 
corticosteroid administration, and prolonged immobility 
are also considered important risk factors; moreover, 
women are more prone to develop CIPNM than men (9). 
This study was designed and performed for evaluating 
peripheral paresis in patients hospitalized in a pediatric 
ICU (PICU) ward and for identifying risk factors for 
CIPNM; the patients had no history of known neurologic 
disorders or events and did not develop them during the 
hospitalization.
Materials & Methods
We conducted an observational and analytic cross-
sectional study and evaluated 57 hospitalized patients 
admitted to the PICU of the Tabriz Pediatric Educational 
Therapeutic Center between July 2007 and July 2010. 
In the 2 years, patients (age range, 1 month to 14 years) 
who had received mechanical ventilation for at least 1 
week were recruited. The incidence of CIPNM and the 
related factors were evaluated. 
Patients with the following conditions were excluded 
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Discussion
In the present study, we evaluated the prevalence of 
and the related factors that cause CIPNM in patients 
admitted in the PICU of the Tabriz Pediatric Educational 
Therapeutic Hospital. CIPNM was diagnosed in 22.8% 
of the patients. The percentage of CIPNM in our study 
patients was lower than that reported in previous studies. 
The results of a previous study showed that the prevalence 
of CIPNM varied from 25% to 77% in PICU patients. 
This prevalence was reported in the patients who were 
hospitalized and had received mechanical ventilation 
in the PICU for at least 7 days (10). Our study patients 
had also received mechanical ventilation for at least 7 
days. Numerous reasons that can explain this difference 
and the extent of reported area are influential. One of 
the main objectives of this study was to evaluate the risk 
factors related to CIPNM. One of the reasons for the 
difference in the prevalence of CIPNM in the patients 
of different studies is the heterogeneity of the probable 
risk factors in these patients. For instance, 70% of the 
patients with sepsis or systemic inflammatory response 
syndrome (SIRS) and up to 100% of the patients with 
multiorgan dysfunction have been shown to develop 
CIPNM during their hospitalization in the PICU (11,3). 
However, the diagnosis of CIPNM is difficult in children 
(12). In most of the CIPNM studies, CIPNM was first 
diagnosed clinically and electrodiagnostic tests were 
only performed if required (13). However, only 58% of 
the children who were clinically diagnosed with CIPNM 
were confirmed to have the syndrome (10). 
In the present study, the diagnosis of CIPNM was 
confirmed using gold standard tests (electrodiagnostic 
tests) in all patients. Therefore, all 13 patients diagnosed 
with CIPNM were confirmed to have the syndrome and 
the remaining patients were not affected. This is the 
most important advantage of our study. One of the other 
probable causes for the difference in the prevalence of 
CIPNM in the patients of different studies is the lack 
of a unanimous definition of the status (5). When we 
evaluated the related causes of CIPNM in the present 
study, we observed that the percentage of patients with 
sepsis and multiorgan dysfunction was significantly 
higher in the CIPNM group than in the non-CIPNM 
group. However, the administration of midazolam was 
significantly higher in the non-CIPNM group than in 
was kept confidential.
Data were analyzed using SPSS16, and the quantitative 
variables were compared using the Mann–Whitney U 
test. The qualitative variables were compared using the 
chi-square test or Fisher’s exact test. The independent 
parameters were determined using the logistic regression 
test. A p value ≤0.05 was considered statistically 
significant. The data were presented as mean ± SD, 
frequency, and percentage values.
Results
Out of the 57 patients, 44 (77.2%) were classified 
into the non-CIPNM group and 13 (22.8%) were 
classified into the CIPNM group. The comparison of 
the demographic data of the 2 groups is summarized 
in table 1. The percentage of sepsis and multiorgan 
dysfunction was significantly higher in the CIPNM 
group than in the non-CIPNM group (table 2). The 
causes of multiorgan dysfunction in the CIPNM group 
were sepsis (5 patients), coronary heart disease (CHD; 
1 patient), severe pneumonia (1 patient), poisoning (1 
patient), tyrosinemia (1 patient), and ischemic–hypoxic 
encephalopathy (1 patient). The causes of multiorgan 
failure in the non-CIPNM group were CHD (6 patients), 
sepsis (3 patients), pneumonia (4 patients), neutropenia 
(3 patients), medicinal reaction (1 patient), brain 
hemorrhage (1 patient), and pneumomediastinum (1 
patient). The percentage of midazolam administration 
was significantly higher in the non-CIPNM group than 
in the CIPNM group (p = 0.01). The CIPNM patients 
were followed up after 6 weeks. Two patients had 
died, 8 patients showed complete remission, and 3 
patients showed no or slight remission. There were no 
statistically significant intergroup differences in the other 
parameters. In the multivariable analysis, there were 
no significant intergroup differences in the percentage 
of patients showing multiorgan dysfunction (exp[B] 
= 4.9; p = 0.08). The percentage of patients receiving 
midazolam was significantly and independently higher 
in the non-CIPNM group than in the CIPNM group 
(exp[B] = 0.1; p = 0.01). The percentage of patients with 
sepsis was significantly and independently higher in the 
CIPNM group than in the non-CIPNM group (exp[B] = 
7.1; p = 0.04).
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were hospitalized in the PICU and 32 developed CIPNM. 
Their results showed that midazolam administration had 
no significant relationship with CIPNM (19). In their 
study, the administered midazolam dose was considered 
only up to the seventh day of mechanical ventilation. 
We observed no significant relationship between the 
midazolam dose and the development of CIPNM. The 
protective mechanism of midazolam is not clear in 
this study; however, midazolam may probably have an 
impact on the improved recovery shown by the patients. 
Further clinical trials need to be conducted for obtaining 
decisive results.
In conclusion, the percentage of patients with sepsis 
and multiorgan dysfunction was significantly higher in 
the CIPNM group than in the non-CIPNM group. The 
percentage of pancuronium, steroid, and aminoglycoside 
administration was not significantly different between 
the 2 groups. In the multivariable analysis, sepsis was 
found to be an independent risk factor for CIPNM 
and midazolam administration was found to be an 
independent protective factor against CIPNM. The 
results of our study show that sepsis is an independent 
risk factor for CIPNM in children hospitalized in a 
PICU. Therefore, strict and early care of these patients 
and early treatment can prevent the incidence of CIPNM. 
Furthermore, midazolam administration had a protective 
effect against CIPNM. Controlled clinical trials need to 
be conducted to confirm these results.
the CIPNM group. There was no significant difference 
in the age, sex, duration of hospitalization, immobility, 
duration of mechanical ventilation, mortality and 
morbidity rates, and administration of pancuronium, 
steroid, and aminoglycoside between the 2 groups. In 
the multivariable analysis, sepsis was found to be an 
independent risk factor for CIPNM, and midazolam 
administration was found to an independent protective 
factor against CIPNM. The results of the previous 
studies are varied. Hermans et al. concluded that sepsis, 
multiorgan dysfunction, and SIRS were the major risk 
factors associated with CIPNM (10). Pati et al. observed 
that sepsis, SIRS, corticosteroid and aminoglycoside 
administration, and multiorgan dysfunction were the 
risk factors associated with CIPNM (14). Shceickert 
et al. reported immobility as a risk factor for CIPNM 
(15). In other studies, parameters associated with 
the development of CIPNM were the duration of 
mechanical ventilation; duration of hospitalization and 
PICU stay; aminoglycoside administration; sex (women 
are more prone to develop CIPNM); severity of the 
primary disease; and corticosteroid, catecholamine, and 
vasopressor administration. However, in some studies, 
aminoglycoside and corticosteroid administration 
was not related to the development of CIPNM (10). 
In a study performed by Hermans et al., corticosteroid 
administration played a protective role against CIPNM 
(16). Therefore, findings of different studies on CIPNM 
are highly varied and sometimes paradoxical. Deem et 
al. concluded that identification of risk factors is very 
difficult, considering the complicated status of the 
patients in the PICU (17). De Jonghe et al. reported that 
the small number of patients in the studies on CIPNM 
is the greatest limitation in identifying factors related 
to CIPNM. In addition, the varied selection criteria and 
definitions can be the reason for the inability to attain 
a decisive conclusion (18). The small sample size of 
the CIPNM patients was the main limitation of our 
study. However, a definitive diagnosis of CIPNM can 
compensate for this limitation to some extent. Although 
the relationship between sepsis and CIPNM has been 
confirmed in different studies, our study reported the 
protective role of midazolam administration for the first 
time. The only study that was similar to our study was 
conducted by de Letter et al. In their study, 98 children 
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Table 1: The demographic data of non-CIPNM and CIPNM patients
p-valueCIPNMNon-CIPNMVariable





0.709.0 ± 5.49.5 ± 5.7PRISM score at the time of admission
0.4924.5 ± 11.825.1 ± 17.3Duration of mechanical ventilation (days)
0.5726.5 ± 12.228 ± 18.6PICU stay (days)
Table 2: The risk factors in non-CIPNM and CIPNM patients
p-valueCIPNMNon-CIPNMVariable
0.015 (38.5%)3 (6.8%)Sepsis
0.0310 (76.9%)19 (48.2%)Multiorgan failure
0.0681 (7.7%)4 (9.1%)Prolonged immobility
0.581 (7.7%)5 (11.4%)Malnutrition
0.017 (53.8%)39 (88.6%)Midazolam administration
0.3327 ± 13.321.1 ± 17.1Duration of midazolam administration (days)
0.563 (23.1%)9 (20.5%)Pancuronium administration
0.502.0 ± 1.02.5 ± 0.8Duration of pancuronium administration (days)
0.3310 (76.9%)26 (59.1%)Steroid administration
0.9018.2 ± 10.320 ± 19.4Duration of steroid administration (days)
0.337 (53.8%)17 (38.6%)Aminoglycoside administration
0.0616.8 ± 3.712.3 ± 5.2Duration of aminoglycoside administration (days)
0.222 (15.2%)2 (4.5%)Prognosis (death)
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